Vaccine manufacturers AstraZeneca and Novavax have said that their respective shots provide protection against the latest COVID-19 variant Omicron. This comes in the wake of UK data which has suggested that Omicron causes fewer hospitalisations than the Delta variant.
Novavax Inc has said that early data showed its vaccine – authorised for use this week by EU regulators and the World Health Organization (WHO), but yet to be approved in the US – generated an immune response against Omicron.
